XtalPi is a Chinese tech startup specializing in AI-powered drug discovery and molecular modeling solutions.
XtalPi launched Kodexia, a platform that combines generative AI, biological modeling, and automated experiments to design siRNA therapies. The platform supports six internal programs across several disease areas.
XtalPi has started pharmacology, safety and manufacturing studies for a hair loss drug candidate ahead of a planned Investigational New Drug application.
XtalPi and Fangda Carbon have put a predictive AI model into operation to evaluate raw materials and optimize graphite electrode formulations.
XtalPi has entered a strategic partnership with an international biopharmaceutical company to develop oral small molecule therapeutics targeting a GPCR receptor, with a potential deal value exceeding $400 million.
XtalPi unveiled its new AI-driven XGlue platform at the 2026 International Symposium on Molecular Glue Drug Discovery in Shanghai, aiming to accelerate systematic discovery of molecular glue therapeutics.
XtalPi and DoveTree Medicines have announced a strategic collaboration worth up to $6 billion to leverage AI and robotics in drug discovery, focusing on oncology, immunology, and other therapeutic areas.
Daily report covering major AI developments and industry news, with both top stories and complete market updates